Absence of Rejection in Cryopreserved Saphenous Vein Allografts for Hemodialysis

Baraldi, A.; Manenti, Antonio; A, Di Felice; Grosoli, M; Furci, Lucinda; Leonelli, Marco; Manca, Jean; Roncaglia, R; Lusvarghi, E

doi:10.1097/00002480-198907000-00006

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over a period of more than 5 years, 1 15 cryopreserved vein allografts were implanted in 87 limbs to the distal popliteal (14) or tibial (101) arteries. The indication for surgery was rest pain in 56 procedures (49%), gangrene in 36 (31%), claudication in 21 (18%), and replacement of aneurysmal allografts in 2.…”

Section: Methodsmentioning

confidence: 99%

Cryopreserved Saphenous Vein Allografts for Below-Knee Lower Extremity Revascularization

Martin

Edwards²,

Mulherin³

et al. 1994

Annals of Surgery

View full text Add to dashboard Cite

ObjectiveCryopreserved saphenous vein allografts have been offered as an alternative conduit for bypass in ischemic limbs. The ResultsThere was no significant difference in patency related to site of proximal or distal anastomosis, patency of runoff vessels, use of anticoagulation, age, sex, diabetes, hypertension, smoking, indication, source of graft, or use of multiple segments. Revision was required in six grafts for aneurysmal dilatation. Histologic examination of explanted sections of allografts showed no immune response, and immunosuppressive drugs were not used. ConclusionsAlthough limb salvage has been satisfactory, long-term patency rates for cryopreserved vein allografts are poor when compared with autogenous vein. The cost of cryopreserved allografts far exceeds that of prosthetic grafts, for which comparable and superior results have been reported. Use of cryopreserved vein allografts should be reserved for situations in which adequate lengths of autogenous vein do not exist and the risk of infection of prosthetic grafts is high. 664

show abstract

Section: Methodsmentioning

confidence: 99%

Cryopreserved Saphenous Vein Allografts for Below-Knee Lower Extremity Revascularization

Martin

Edwards²,

Mulherin³

et al. 1994

Annals of Surgery

View full text Add to dashboard Cite

show abstract

“…Exposure to allogeneic antigen raises the possibility of immune responses with subsequent sensitisation. When assessed by Baraldi and colleagues cryopreserved vessels were found to have minimal T-cell infiltration despite no blood group or human leucocyte antigen matching (11). However, immunological reactivity measured by antibody generation (PRA) showed that sensitisation does occur following the use of dimethyl sulphoxide cryopreserved vessels and this may have major impact on future transplantation (12, 13).…”

mentioning

confidence: 99%

Long-Term Results of Biological Grafts for Haemodialysis Vascular Access

Inston

2015

J Vasc Access

View full text Add to dashboard Cite

The quest for suitable conduits for dialysis access has continued since the first patients were dialysed. Whilst synthetic grafts made from expanded polytetrafluoroethylene (ePTFE) have been the main definitive option after autologous arteriovenous fistulas they have a number of drawbacks, which has led to the use and development of biological grafts such as autografts, homografts or xenografts. Technology continues to improve and currently biosynthetic options are available which may combine the benefits of a readily available product without the drawbacks of PTFE. The history and evidence of biological options for haemodialysis access are discussed.

show abstract

Management of infected hemodialysis access grafts using cryopreserved human vein allografts

Lin

Brinkman

Terramani

et al. 2002

The American Journal of Surgery

View full text Add to dashboard Cite

Absence of Rejection in Cryopreserved Saphenous Vein Allografts for Hemodialysis

Cited by 9 publications

References 0 publications

Cryopreserved Saphenous Vein Allografts for Below-Knee Lower Extremity Revascularization

Cryopreserved Saphenous Vein Allografts for Below-Knee Lower Extremity Revascularization

Long-Term Results of Biological Grafts for Haemodialysis Vascular Access

Management of infected hemodialysis access grafts using cryopreserved human vein allografts

Contact Info

Product

Resources

About